格隆汇2月10日丨恒瑞医药(600276.SH)公布，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监 督管理局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入 优先审评程序。 公司注射用瑞康曲妥珠单抗已于2025年5月在国内获批上市，适用于治疗存在HER2（ERBB2）激活突 变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患 者。 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-024 一、药品的基本情况 药品名称：注射用瑞康曲妥珠单抗 剂型：注射剂 受理号：CXSS2600018 申报阶段：上市 申请人：苏州盛迪亚生物医药有限公司 拟定适应症（或功能主治）：本品适用于治疗经奥沙利铂、氟尿嘧啶和伊立 替康治疗失败的 HER2 阳性结直肠癌成人患者。 江苏恒瑞医药股份有限公司 关于药品上市许可申请获受理并纳入优先审评程序 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司苏州盛迪亚 生物医药有限公司收到国家药品监督管理局（以下简称"国家药监局"）下发的 《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已 被纳入优先审评程序。现将相关情况公告如下： 在经奥沙利铂、氟尿嘧啶类和伊立替康治疗失败的 HER2 阳性晚期结直肠癌受试 者中的有效性和安全性，并探索该药物的免疫原性及药代动力学特征。本研究由 上海高博肿瘤医院李进院长和浙江大学医学院附属第二医院袁瑛 ...

恒瑞医药公告称，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，注射用 瑞康曲妥珠单抗的药品上市许可申请获受理并纳入优先审评程序。该药品已于2025年5月在国内获批用 于治疗特定肺癌，此次新适应症为治疗经奥沙利铂等治疗失败的HER2阳性结直肠癌成人患者。截至目 前，相关项目累计研发投入约17.73亿元。药品研发上市存在不确定性，公司将及时披露进展。 ...

Core Insights - The report from Southwest Securities indicates that first-line treatment for driver gene-negative NSCLC (non-small cell lung cancer) patients primarily relies on PD(L)-1 ± chemotherapy, with projected market sizes for immune drugs in this segment reaching approximately 7.5 billion yuan in China and 18 billion yuan in the U.S. by 2030 [1] Group 1: Market Overview - The driver gene-negative segment accounts for 31% of newly diagnosed NSCLC patients in both China and the U.S. [1] - The projected market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is estimated to be around 7.5 billion yuan in China and 18 billion yuan in the U.S. by 2030 [1] Group 2: Next-Generation Immunotherapy - Next-generation immunotherapy options for NSCLC are advancing, including bispecific antibodies and IO+ADC (immuno-oncology plus antibody-drug conjugates) [2] - Current PD(L)-1 drugs, such as Pembrolizumab and Atezolizumab, have established their clinical position but face limitations in long-term efficacy, particularly in patients with low PD-L1 expression [2] Group 3: Bispecific Antibody Treatment - Bispecific antibodies can bind to two antigens or epitopes, balancing safety and efficacy, with the approval of Ivorisumab in 2024 expected to stimulate interest in PD-(L)1/VEGF therapies [3] - The clinical data and technological pathways for bispecific antibodies are gaining recognition, with the potential for tri-specific antibodies to become a new trend in immuno-oncology treatment [3] Group 4: IO+ADC Treatment - ADCs combine cytotoxic drugs with monoclonal antibodies targeting tumors, offering precise delivery and effective treatment with lower toxicity [3] - Clinical results for TROP2 ADC combined with K-drug show comparable ORR and PFS data to K-drug plus chemotherapy, providing new solutions for patients intolerant to chemotherapy [3]

2025年5月下旬，港股三生制药股价单日暴涨超30%，子公司三生国健在A股市场更是连续四个交易日 斩获"20CM"涨停。点燃这场资本狂欢导火索的，是一笔高达60.5亿美元的对外授权合作交易——辉瑞 拿下其抗癌双抗药物SSGJ-707海外权益，仅首付款就达到12.5亿美元。 而这，仅仅只是拉开了全年BD热潮的序幕。 从三生制药和辉瑞的双抗交易刷新国内BD首付款记录开始，信达生物、舶望制药、恒瑞医药 （600276）等公司接连宣布与武田、诺华、GSK等跨国药企达成数十亿乃至上百亿美元的合作。 过去一年，"BD"无疑是医药行业贯穿全年的核心关键词。据医药魔方研报数据披露，2025年国内创新 药对外授权交易总交易额超1300亿美元，仅首付款就超70亿美元，在ADC、双抗、GLP-1等前沿赛道 上，更是展现出影响细分赛道未来格局的潜力。 除了金额的飙升，BD交易模式的演变同样反映出产业关系的变迁。从单纯的licenseout到New-Co和Co- co模式（共同开发、共同商业化），乃至于共建"风险共担、利益共享"的生态，从单纯的"卖产 品"到"卖平台"，传统药企强势崛起，中小biotech多点开花。 刘立鹤同样提到，相 ...

Core Viewpoint - The simultaneous release of refinancing optimization measures by Shanghai, Shenzhen, and Beijing stock exchanges marks a significant transformation in China's capital market, aimed at enhancing capital allocation efficiency and reshaping the A-share market landscape [1]. Group 1: Policy Framework and Differences - The policy frameworks of the three exchanges are highly similar, focusing on "supporting the strong, limiting the weak, promoting innovation, and enhancing convenience and regulation" [2]. - Shanghai Stock Exchange emphasizes "main board" characteristics, tailoring financing rules for large, mature technology companies [2]. - Shenzhen Stock Exchange adopts a bolder stance on supporting technology innovation, easing fundraising restrictions for growth-oriented enterprises [2]. - Beijing Stock Exchange focuses on "innovative small and medium-sized enterprises," addressing their financing challenges with flexible policies [2]. Group 2: Strategic Insights on Separate Announcements - The decision to release policies on the same day rather than a joint announcement reflects the nuanced wisdom of tiered regulation in China's capital market [3]. - Different market positioning allows each exchange to cater to the unique characteristics and needs of the enterprises they serve, avoiding a one-size-fits-all approach [3]. - The simultaneous release creates a strong policy resonance, reinforcing market perception of deepening capital market reforms while maintaining the distinct identities of each exchange [3]. Group 3: Deep Impacts on Market Perception - The new measures aim to shift the long-standing fear of "blood-sucking" effects of refinancing, which was believed to drain market funds and destabilize the market [4]. - The principle of "supporting the strong, limiting the weak" will act as a catalyst for market differentiation, favoring quality companies, especially in hard technology, while raising barriers for poorly performing firms [4]. - The policy directs resources towards "new productive forces," providing strong support for leading companies in sectors like semiconductors, AI, biomedicine, and high-end manufacturing [5]. - Allowing companies that have experienced stock price declines to raise funds through methods like private placements and convertible bonds offers a lifeline to solid businesses facing temporary challenges [6]. - A complete regulatory loop is established, tightening post-fundraising supervision while relaxing initial approvals, transforming refinancing from a mere "money-raising tool" to an "engine" for corporate development [7]. Group 4: Implications for Investors - The coordinated actions of the three exchanges signify the entry of China's refinancing mechanism into a "precise drip irrigation" era, providing tailored financing support for different types of enterprises [8]. - Investors are advised to focus on genuinely innovative and well-governed companies while avoiding those that merely chase trends without substance [8]. - The transformation of refinancing from a "blood-sucking machine" to a "blood-producing pump" is expected to enhance the value discovery function of the A-share market, leading to a healthier and more vibrant capital market [8].

截至2026年2月10日 13:20，中证医药及医疗器械创新指数(931484)上涨0.57%，成分股惠泰医疗上涨 4.86%，海思科上涨3.61%，康龙化成上涨2.55%，药明康德上涨2.31%，恩华药业上涨1.89%。医疗创新 ETF(516820)上涨0.55%，最新价报0.37元。 消息面上，2月9日，1-8批国家集采药品新一轮接续采购开标产生拟中选结果。本次接续采购涉及1-8批 国家集采的316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系统、 消化系统等26个治疗领域。全国5.1万家医药机构参加报量，共1091家国内外企业的4623个产品参与投 标，1020家企业的4163个产品获得拟中选资格。 东海证券指出，小核酸赛道的高景气度持续延续，从罕见病向慢病领域加速渗透，市场规模持续扩容； 跨国药企布局意愿提升，国内本土企业技术获国际认可，出海路径清晰，供应链优势凸显，板块投资价 值持续提升。后续投资建议聚焦三大核心主线：一是具备核心递送技术、拥有国际合作潜力的新锐 biotech；二是布局慢病领域（心血管、代谢等）、管线进度领先、可复制Leqvio商业化路径的行业龙 头；三 ...

Summary of the Conference Call for Heptares Therapeutics Company Overview - Heptares Therapeutics is a biotechnology company focused on innovative drug development, particularly in the fields of immunology and oncology. The company has established a strong position in the Chinese market for innovative drug business development (BD) transactions, contributing significantly to the industry. Key Points Industry Insights - The total value of BD transactions in China's innovative drug sector is projected to reach $135 billion in 2025, with Heptares contributing approximately $7 billion [2][10] - 2025 is noted as a year with a high concentration of BD events, leading to explosive growth in the industry, driven by major companies like Heptares and Heng Rui [3] Financial Performance - Heptares is expected to achieve a revenue of approximately $170 million in 2025, with a net profit close to $100 million [4][16] - For 2026, revenue is projected to grow to about $300 million, corresponding to a profit of approximately $160 million to $170 million, representing a year-on-year growth of over 60% [4][16] - As of mid-2025, Heptares held $320 million in cash, indicating a strong financial position supported by previous BD transactions and investments from major stakeholders like AstraZeneca [7] Core Technologies and Platforms - Heptares has developed several key technology platforms, including the Harbor Mice platform for fully human antibodies and the HBIAS platform for TCE bispecific antibodies [8][9] - The company’s platforms enhance molecular adaptability and research efficiency, allowing for the development of differentiated pipelines, including CTLA-4 antibody 4,003 and TSLP monoclonal and bispecific antibodies [2][5] Clinical Development Highlights - In the immunology field, the TSLP long-acting fully human antibody 9,378 has a half-life two to three times longer than currently marketed TSLP antibodies and can be administered subcutaneously [12] - In oncology, the CTLA-4 antibody 4,003 has shown promising Phase II clinical data in microsatellite instability tumors, positioning it as a potential best-in-class product [12][14] Strategic Partnerships - Heptares has formed significant partnerships, including a major collaboration with AstraZeneca involving a $175 million upfront payment and milestone payments totaling $4.4 billion [2][10] - The company has also established partnerships with other multinational corporations such as Pfizer and BMS, enhancing its market presence and collaborative potential [10] Future Outlook - The company anticipates stable performance growth in 2026, with a focus on clinical data development rather than solely event-driven factors [3][17] - Heptares aims to complete 1-2 new transactions annually, contributing to ongoing revenue growth and cash flow generation [16] - The overall industry trend is shifting towards performance growth and clinical advancement, with expectations for strong financial results in upcoming reports [17] Valuation and Market Position - Heptares is currently valued at approximately HKD 20 billion, with a projected price-to-earnings ratio of 15x for 2025, 8x for 2026, and 10x for 2027 [5][16] - The company is viewed as a quality investment opportunity due to its low valuation and strong growth potential in the innovative drug sector [17]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]

数据显示，截至2026年1月30日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、迈瑞医疗、恒瑞医药、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.9%。 截至2026年2月10日 10:28，中证医药及医疗器械创新指数(931484)上涨0.50%，成分股海思科上涨 3.59%，药明康德上涨2.11%，康龙化成上涨1.76%，惠泰医疗上涨1.75%，兴齐眼药上涨1.66%。医疗创 新ETF(516820)上涨0.27%，最新价报0.37元。 消息面上，韩国一家数字医疗初创企业9日说，已开发出一款基于人工智能(AI)的数字诊断平台，可以 帮助人们在家尽早发现心脏病发作的先兆。 平安证券指出，2026年设备更新政策持续加码，叠加紧密型县域医共体建设与强基工程推进，基层医疗 设备规模化采购空间打开；国产头部企业如迈瑞医疗、联影医疗、开立医疗招投标金额同比分别增长 36%、34%、77%，行业向上拐点趋势明确。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备 ...